TESARO (TSRO) Misses Q2 EPS by 33c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. CVS
9. SPY
10. XYZ

Go back to TESARO (TSRO) Misses Q2 EPS by 33c

TESARO Announces Second-Quarter 2017 Operating Results

August 8, 2017 4:05 PM EDT

ZEJULA is the most prescribed PARP inhibitor in U.S.; Q2 net sales totaled $26 million in first quarter of availabilityRecently opened European niraparib EAP has enrolled 200 patientsVARUBY oral launch now underway in Europe Dose-escalation of TSR-022 (anti-TIM-3) completed and combination trial with TSR-042 (anti-PD-1) initiatedRegulatory strategy defined with FDA for TSR-042 in MSI-high cancers and registration study ongoingLicense agreement signed with Takeda in July for niraparib development and commercialization in Japan and certain other countries with a $100 million upfront payment and up... More